Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 - Flinn, Ian W.; Neuberg, Donna S.; Grever, Michael R.; Dewald, Gordon W.; Bennett, John M.; Paietta, Elisabeth M.; Hussein, Mohamad A.; Appelbaum, Frederick R.; Larson, Richard A.; Moore, Dennis F.; Tallman, Martin S. (Journal of clinical oncology, 2007)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Female; Hematologic and hematopoietic diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Logistic Models; Male; Medical sciences; Middle Aged; Neoplasms, Second Primary - epidemiology; Prognosis; Tumors; Vidarabine - administration & dosage; Vidarabine - adverse effects; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use; Antineoplastic agent; Phase III trial; Human; Purine nucleotide; Malignant hemopathy; Alkylating agent; Oxazaphosphinane derivatives; Chemotherapy; Cyclophosphamide; Chronic lymphocytic leukemia; Cancerology; Fludarabine; Treatment; Antimetabolic; Nitrogen mustard; Clinical trial; Fluorine Organic compounds; Comparative study